Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Rhea-AI Summary

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology and oncogene amplified cancers, has announced its participation in Piper Sandler's 36th Annual Healthcare Conference.

President and CEO Zachary Hornby will participate in a fireside chat on Wednesday, December 4, 2024, at 3:30 p.m. ET in New York. The session will be available via live and archived webcast through the company's website under the Investors section.

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Piper Sandler’s 36^th Annual Healthcare Conference.

A fireside chat session is scheduled for Wednesday, December 4, 2024, in New York, NY, at 3:30 p.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website and can be accessed via this link: https://event.webcasts.com/starthere.jsp?ei=1697442&tp_key=52e6709a8e.

About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapy (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. Boundless Bio’s second ecDTx, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical trial in colorectal cancer patients with BRAF^V600E or KRAS^G12C mutations and resistance gene amplifications. Leveraging its Spyglass platform, Boundless Bio has an additional program (ecDTx 3) advancing through preclinical development and discovery. Boundless Bio is headquartered in San Diego, CA.
For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and X.

Contacts:
Ben Flaum, Boundless Bio
bflaum@boundlessbio.com

Investors
THRUST Strategic Communications
Renee Leck
renee@thrustsc.com

FAQ

When is Boundless Bio (BOLD) presenting at the Piper Sandler Healthcare Conference 2024?

Boundless Bio will present at the Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 3:30 p.m. ET in New York.

How can I watch Boundless Bio's (BOLD) presentation at the Piper Sandler Conference?

The presentation can be accessed via live and archived webcast through Boundless Bio's website under the Events & Presentations section in the Investors area.

What type of cancer research does Boundless Bio (BOLD) focus on?

Boundless Bio focuses on extrachromosomal DNA (ecDNA) biology to develop therapies for previously intractable oncogene amplified cancers.

Who will represent Boundless Bio (BOLD) at the Piper Sandler Healthcare Conference?

Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will represent the company at the conference.